SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.085

Change

+0.03 (+69.32)%

Market Cap

N/A

Volume

7.09K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.69 (-1.02%)

USD 209.55B
AMGN Amgen Inc

-3.61 (-1.30%)

USD 164.90B
GILD Gilead Sciences Inc

-0.21 (-0.20%)

USD 133.70B
SNY Sanofi ADR

+0.03 (+0.06%)

USD 125.78B
BIIB Biogen Inc

-2.12 (-1.79%)

USD 18.00B
GRFS Grifols SA ADR

-0.07 (-0.99%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.44 (+4.83%)

USD 0.19B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.07 (-7.87%)

USD 0.02B
SCLX Scilex Holding Company

-1.32 (-21.93%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.52% 20% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.52% 20% F 9% A-
Trailing 12 Months  
Capital Gain -69.31% 20% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.31% 20% F 13% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.93% 20% F 8% B-
Dividend Return -27.93% 20% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.15% 20% F 40% F
Risk Adjusted Return -63.26% 30% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector